company background image
SHE logo

Shedir Pharma Group BIT:SHE Stock Report

Last Price

€3.68

Market Cap

€41.8m

7D

-0.5%

1Y

-21.0%

Updated

22 May, 2024

Data

Company Financials

Shedir Pharma Group S.p.A.

BIT:SHE Stock Report

Market Cap: €41.8m

SHE Stock Overview

Through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy.

SHE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends2/6

Shedir Pharma Group S.p.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shedir Pharma Group
Historical stock prices
Current Share Price€3.68
52 Week High€4.94
52 Week Low€3.34
Beta0.73
1 Month Change1.10%
3 Month Change-6.60%
1 Year Change-21.03%
3 Year Change-14.62%
5 Year Changen/a
Change since IPO-47.12%

Recent News & Updates

Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 05
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Recent updates

Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 05
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Oct 05
Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem

Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?

Apr 06
Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?

What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 30
What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Shareholder Returns

SHEIT PharmaceuticalsIT Market
7D-0.5%1.3%-1.7%
1Y-21.0%12.7%22.1%

Return vs Industry: SHE underperformed the Italian Pharmaceuticals industry which returned 12.7% over the past year.

Return vs Market: SHE underperformed the Italian Market which returned 22.1% over the past year.

Price Volatility

Is SHE's price volatile compared to industry and market?
SHE volatility
SHE Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement4.5%
10% most volatile stocks in IT Market8.1%
10% least volatile stocks in IT Market2.8%

Stable Share Price: SHE has not had significant price volatility in the past 3 months.

Volatility Over Time: SHE's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200879Antonio Scalawww.shedirpharma.com

Shedir Pharma Group S.p.A., through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. It provides products for andrological, cardiovascular, dermatological, hematological, energy, gastrointestinal, gynecological, metabolic, neurological, dental, ophthalmic, osteoarticular, otologic, respiratory, and trichological diseases. The company offers its products through a network of sales agents, wholesalers, and pharmacies.

Shedir Pharma Group S.p.A. Fundamentals Summary

How do Shedir Pharma Group's earnings and revenue compare to its market cap?
SHE fundamental statistics
Market cap€41.81m
Earnings (TTM)€5.62m
Revenue (TTM)€59.39m

7.4x

P/E Ratio

0.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SHE income statement (TTM)
Revenue€59.39m
Cost of Revenue€41.02m
Gross Profit€18.37m
Other Expenses€12.75m
Earnings€5.62m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.49
Gross Margin30.93%
Net Profit Margin9.46%
Debt/Equity Ratio13.1%

How did SHE perform over the long term?

See historical performance and comparison

Dividends

4.8%

Current Dividend Yield

34%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.